The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy-Reference-Cited by-同舟云学术

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

Published:2013-01-12 Issue:6 Volume:21 Page:1655-1663
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Navari Rudolph M.,Nagy Cindy K.,Gray Sarah E.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-012-1710-6.pdf

Reference39 articles.

1. Bloechl-Daum B, Deuson RR, Panagiotis M et al (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478

2. Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69:515–533

3. Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6:1073–1084

4. Curran MP, Robinson DM (2009) Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69:1853–1858

5. Sankhala KK, Pandya DM, Sarantopoulos J et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607–1614

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success;Critical Reviews in Oncology/Hematology;2024-09

2. Cannabis for Refractory Chemotherapy-Induced Nausea and Vomiting;Journal of Clinical Oncology;2024-08-20

3. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting;Expert Opinion on Drug Metabolism & Toxicology;2024-06-02

4. The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study;Supportive Care in Cancer;2024-04-17

5. Expertise Area 3.2: Testicular cancer;Rare and Complex Urology;2024